MindWalk Unveils B Cell Llama™ Nanobody Platform Targeting $50B Bispecific Antibody Market
MindWalk launched B Cell Llama™ platform for VHH nanobody discovery, aiming to tap into projected $50B bispecific antibody market by 2030, using LensAI™ to guide target selection and candidate triage. A peer-reviewed study showed multivalent nanobodies achieved sub-nanomolar potency, 10–25× increase over monovalent formats, and trivalent constructs neutralized resistant variants.
1. Platform Launch and Capabilities
MindWalk launched B Cell Llama™, a platform isolating VHH nanobodies from immunized llamas and applying LensAI™ across immunogen design, candidate triage, multispecific construct modeling, and immunogenicity prediction to accelerate bispecific antibody and cell therapy discovery.
2. Peer-Reviewed Study Findings
A study published in Biomacromolecules demonstrated multivalent VHH constructs achieved sub-nanomolar potency—10 to 25 times greater than monovalent formats—while a trivalent design neutralized variants that escaped monovalent and approved antibody therapies. The research also highlighted a potential immune-priming effect of VHH-nanoparticle complexes.
3. Market Opportunity and Pipeline Integration
B Cell Llama™ positions MindWalk to capture part of the projected $50 billion bispecific antibody market by 2030 and complements existing dengue, universal influenza, GLP-1 longevity, and oncology programs. The platform’s access to natural sequence diversity and AI-guided precision aims to advance new bispecific and cell therapy candidates.